Pfizer News | finanzen.ch

Pfizer Aktie VALOR 1065272 / ISIN ARDEUT111424

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

23.06.23	Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
22.06.23	Pfizer Declares Third-Quarter 2023 Dividend (Businesswire)
21.06.23	Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval (Businesswire)
20.06.23	Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts (Businesswire)
06.06.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.23	Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
31.05.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults (Businesswire)
30.05.23	Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (Businesswire)
26.05.23	Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission (RSS)
25.05.23	Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting (Businesswire)
25.05.23	Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 (Businesswire)
18.05.23	FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization (Businesswire)
17.05.23	Pfizer Prices $31,000,000,000 Debt Offering (Businesswire)
15.05.23	Pfizer Announces Proposed Notes Offering (Businesswire)
02.05.23	Pfizer Reports First-Quarter 2023 Results (Businesswire)
27.04.23	U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children (Businesswire)
26.04.23	Pfizer Declares Second-Quarter 2023 Dividend (Businesswire)
13.04.23	Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 (Businesswire)
04.04.23	FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI (Businesswire)
21.03.23	Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts (Businesswire)
16.03.23	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ (Businesswire)
14.03.23	Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
13.03.23	Pfizer Invests $43 Billion to Battle Cancer (Businesswire)
10.03.23	Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval (Businesswire)
01.03.23	Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
28.02.23	Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults (Businesswire)
27.02.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
22.02.23	Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance (Businesswire)
21.02.23	U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review (Businesswire)
16.02.23	Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study (Businesswire)
16.02.23	Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults (Businesswire)
10.02.23	FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) (Businesswire)
10.02.23	Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program (RSS)
09.02.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
31.01.23	PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE (Businesswire)
17.01.23	Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries (Businesswire)
06.01.23	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children (Businesswire)
03.01.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
28.12.22	U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
26.12.22	Accelleron-Aktie, Porsche-Aktie & Co.: Das wurde aus den 2022er IPOs (finanzen.ch) Regelmässig wird die Börsenlandschaft durch weitere Unternehmen ergänzt - so auch 2022. Diese Neuankömmlinge standen dabei besonders im Fokus der Anleger.» mehr
21.12.22	Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis (Businesswire)
20.12.22	Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts (Businesswire)
10.12.22	Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial (Businesswire)
09.12.22	Pfizer Declares First-Quarter 2023 Dividend (Businesswire)
09.12.22	Tilray Brands' Stockholders Approve Reverse Stock Split; Company Pauses Implementation as It Evaluates Timing and Stock Price (RSS)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (Businesswire)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
07.12.22	U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults (Businesswire)
06.12.22	Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease (Businesswire)
05.12.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	563.50	0.81 %	K V
Swiss Life Hldg	820.00	0.79 %	K V
Nestle	77.30	0.40 %	K V
Part Grp Hldg	1’059.00	0.38 %	K V
Roche Hldg G	257.70	0.35 %	K V
Geberit	616.00	-0.81 %	K V
CieFinRichemont	147.50	-0.84 %	K V
Sonova Hldg	229.90	-0.91 %	K V
Kuehne+Nagel Int	171.70	-0.95 %	K V
Sika	203.80	-1.07 %	K V